Home > Boards > US Listed > Biotechs > BIONDVAX PHARMACUETICALS LTD (BVXV)

BiondVax Announces First Quarter 2020 Financial Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 110
Posts 24,076
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 8:20:36 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 6:32:00 AM
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire (US) - 7/1/2020 6:00:00 AM
BiondVax Announces First Quarter 2020 Financial Results PR Newswire (US) - 6/30/2020 4:01:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/22/2020 1:37:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:11:32 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 6/12/2020 8:04:57 AM
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire (US) - 6/12/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 7:48:38 AM
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoin... PR Newswire (US) - 6/10/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2020 7:44:36 AM
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants PR Newswire (US) - 5/20/2020 6:30:00 AM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 5/13/2020 4:34:19 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/4/2020 10:48:44 AM
BiondVax Announces Upcoming Expiration of Public Warrants PR Newswire (US) - 5/4/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/30/2020 9:40:42 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/24/2020 4:28:59 PM
New Directors Elected to BiondVax's Board of Directors PR Newswire (US) - 3/24/2020 4:01:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/19/2020 1:06:02 PM
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial PR Newswire (US) - 3/19/2020 7:15:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/25/2020 12:42:30 PM
Amended Report of Foreign Issuer (6-k/a) Edgar (US Regulatory) - 2/10/2020 5:22:43 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/10/2020 11:15:24 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/5/2020 3:25:39 PM
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Va... PR Newswire (US) - 2/5/2020 1:00:00 PM
midastouch017   Tuesday, 06/30/20 04:17:20 PM
Re: None
Post # of 373 
BiondVax Announces First Quarter 2020 Financial Results

PR Newswire PR Newswire•June 30, 2020

JERUSALEM, June 30, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its first quarter financial results for the quarter ended March 31, 2020.

First Quarter 2020 Financial Summary


Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.57 (NIS/$US) as at March 31, 2020.

Total operating expenses for the first quarter were NIS 20.0 million (approximately $5.6 million) compared with NIS 7.1 million for the first quarter of 2019.

R&D expenses for the first quarter amounted to NIS 19 million (approximately $5.3 million) compared with NIS 5.7 million for the first quarter of 2019.
Net loss for the first quarter was NIS 3.7 million (approximately $1.0 million) compared to net income of NIS 566 thousand for the first quarter of 2019.
The increase in total operating expenses compared to the first quarter of 2019 was primarily due to expenses related to the ongoing Phase 3 trial and scale-up at our manufacturing facility.

As of March 31, 2020, BiondVax had cash and cash equivalents of NIS 42.5 million (approximately $11.9 million) compared to NIS 72.4 million as of December 31, 2019.

*Tables to follow*

About BiondVax

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of seven completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please visit www.biondvax.com.

https://finance.yahoo.com/news/biondvax-announces-first-quarter-2020-200100410.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist